Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2024 Oct 27;60(11):1760.
doi: 10.3390/medicina60111760.

Bleeding and Thrombotic Events in Hemodialysis Patients with Atrial Fibrillation on Anticoagulation and Antiplatelet Therapy: A 24-Month Cohort Study

Zorica M Dimitrijevic  1   2 , Branka P Mitic  1   2 , Danijela D Tasic  1 , Tamara Vrecic  1 , Karolina Paunovic  1   2 , Sonja Salinger  2   3
Affiliations
Observational Study

Bleeding and Thrombotic Events in Hemodialysis Patients with Atrial Fibrillation on Anticoagulation and Antiplatelet Therapy: A 24-Month Cohort Study

Zorica M Dimitrijevic et al. Medicina (Kaunas). .

Abstract

Background and Objectives: Patients undergoing chronic hemodialysis (HD) are predisposed to both thrombotic and bleeding complications due to the complex interplay of end-stage renal disease (ESRD), cardiovascular comorbidities, and the routine use of anticoagulant and antiplatelet therapies. This study aimed to investigate the incidence of bleeding and thrombotic events in chronic HD patients receiving anticoagulant and antiplatelet therapy, with a specific focus on those with atrial fibrillation (AF). Materials and Methods: A total of 224 patients, with 43 (19%) of them diagnosed with AF, were included in this single-center, observational cohort study conducted over 24 months. The cohort was divided into three groups: patients without anticoagulation, those on warfarin monotherapy, and those on combined warfarin and aspirin therapy. Bleeding events were classified as major, clinically relevant non-major bleeding (CRNMB), or minor bleeding, while thrombotic events included ischemic stroke, myocardial infarction, pulmonary embolism, and arteriovenous fistula thrombosis. Results: Overall, 35.7% of patients experienced a bleeding event, with major bleeding occurring in 9.4%. Patients with AF had significantly higher rates of major bleeding (18.6%) compared to those without AF (7.18%; p = 0.043), especially in the combined therapy group. Mortality due to bleeding was also higher in AF patients (14%). In contrast, thrombotic events occurred in 26.8% of patients, with AF patients experiencing significantly more events (48.8%) compared to non-AF patients (21.5%; p = 0.0006). The hazard ratio (HR) for major bleeding in patients on combined warfarin and aspirin therapy was 2.56 (p = 0.016), while the HR for thrombotic events was 2.34 (p = 0.0202). Conclusions: These findings highlight the increased risks of both bleeding and thrombosis in chronic HD patients with AF, particularly those on combined anticoagulation and antiplatelet therapy.

Keywords: anticoagulation therapy; atrial fibrillation; bleeding; hemodialysis; thrombosis.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Flowchart diagram of the study cohort creation.
See this image and copyright information in PMC

References

    1. Catella J., Bertoletti L., Mismetti P., Ollier E., Samperiz A., Soler S., Suriñach J.M., Mahé I., Lorente M.A., Braester A., et al. Severe renal impairment and risk of bleeding during anticoagulation for venous thromboembolism. J. Thromb. Haemost. 2020;18:1728–1737. doi: 10.1111/jth.14837. - DOI - PubMed
    1. Escolar G., Díaz-Ricart M., Cases A. Uremic platelet dysfunction: Past and present. Curr. Hematol. Rep. 2005;4:359–367. - PubMed
    1. Kozek-Langenecker S.A., Masaki T., Mohammad H., Green W., Mohammad S.F., Cheung A.K. Fibrinogen fragments and platelet dysfunction in uremia. Kidney Int. 1999;56:299–305. doi: 10.1046/j.1523-1755.1999.00518.x. - DOI - PubMed
    1. Soler-Espejo E., Esteve-Pastor M.A., Rivera-Caravaca J.M., Roldan V., Marín F. Reducing bleeding risk in patients on oral anticoagulation therapy. Expert Rev. Cardiovasc. Ther. 2023;21:923–936. doi: 10.1080/14779072.2023.2275662. - DOI - PubMed
    1. Königsbrügge O., Posch F., Antlanger M., Kovarik J., Klauser-Braun R., Kletzmayr J., Schmaldienst S., Auinger M., Zuntner G., Lorenz M., et al. Prevalence of atrial fibrillation and antithrombotic therapy in hemodialysis patients: Cross-sectional results of the Vienna Investigation of AtriaL Fibrillation and Thromboembolism in Patients on HemoDIalysis (VIVALDI) PLoS ONE. 2017;12:e0182798. - PMC - PubMed

Publication types

MeSH terms

LinkOut - more resources